Drug Administration Schedule
"Drug Administration Schedule" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
| Descriptor ID |
D004334
|
| MeSH Number(s) |
E02.319.283
|
| Concept/Terms |
Drug Administration Schedule- Drug Administration Schedule
- Administration Schedule, Drug
- Administration Schedules, Drug
- Drug Administration Schedules
- Schedule, Drug Administration
- Schedules, Drug Administration
|
Below are MeSH descriptors whose meaning is more general than "Drug Administration Schedule".
Below are MeSH descriptors whose meaning is more specific than "Drug Administration Schedule".
This graph shows the total number of publications written about "Drug Administration Schedule" by people in this website by year, and whether "Drug Administration Schedule" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 17 | 17 |
| 1995 | 0 | 12 | 12 |
| 1996 | 0 | 15 | 15 |
| 1997 | 0 | 12 | 12 |
| 1998 | 0 | 16 | 16 |
| 1999 | 0 | 15 | 15 |
| 2000 | 0 | 17 | 17 |
| 2001 | 0 | 32 | 32 |
| 2002 | 0 | 22 | 22 |
| 2003 | 0 | 28 | 28 |
| 2004 | 0 | 25 | 25 |
| 2005 | 0 | 35 | 35 |
| 2006 | 0 | 27 | 27 |
| 2007 | 0 | 22 | 22 |
| 2008 | 1 | 28 | 29 |
| 2009 | 0 | 40 | 40 |
| 2010 | 0 | 20 | 20 |
| 2011 | 0 | 15 | 15 |
| 2012 | 0 | 22 | 22 |
| 2013 | 0 | 27 | 27 |
| 2014 | 0 | 20 | 20 |
| 2015 | 0 | 21 | 21 |
| 2016 | 0 | 25 | 25 |
| 2017 | 0 | 13 | 13 |
| 2018 | 0 | 22 | 22 |
| 2019 | 1 | 23 | 24 |
| 2020 | 0 | 15 | 15 |
| 2021 | 0 | 6 | 6 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Administration Schedule" by people in Profiles.
-
Risk factors for MACE and bleeding in atrial fibrillation patients undergoing surgery: Insights from the bridge trial. J Stroke Cerebrovasc Dis. 2024 Sep; 33(9):107839.
-
Impact of electronic interventions on guideline concordant ordering of rituximab infusion rate. J Oncol Pharm Pract. 2022 Jul; 28(5):1157-1162.
-
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2022 01 01; 107(1):e372-e385.
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.
-
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021 10; 22(10):1438-1447.
-
Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma. JAMA Netw Open. 2021 07 01; 4(7):e2118410.
-
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. BMC Cancer. 2021 Jun 02; 21(1):659.
-
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021 Aug; 17(23):3027-3035.
-
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021 02 06; 397(10273):475-486.
-
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181). Clin Transl Sci. 2021 01; 14(1):277-287.